Facebook
Twitter
LinkedIn
Forward
Submitted by David Salotti on
Group:
Group visibility:
Public - accessible to all site users
The CMHC Education Resource Center offers a single access point for educational resources and online courses featuring the expert content and faculty from CMHC live events. Stay current on the latest clinical research and strategies, while testing your knowledge of essential topics in cardiometabolic risk management and CVD prevention. Select from a comprehensive array of complimentary CME-CE activities in a variety of formats to meet your needs, available on-demand and on-the-go!
Featured Activity
|
Heart failure remains one of the most challenging conditions to manage, with worsening heart failure being a critical area where suboptimal outcomes persist. While foundational therapies such as beta-blockers, ACE inhibitors, mineralocorticoid receptor antagonists, and ARNIs remain integral to heart failure management, advances in our understanding of heart failure pathophysiology have opened the door to newer, innovative therapeutic options, such as SGLT-2i, sCG stimulators and SGLT1/2 inhibitors.
This webcast is designed to deliver expert perspectives through a dynamic combination of didactic presentations and interspersed discussions. Together, we will explore the burden of worsening heart failure, review current treatment approaches, and delve into the clinical application of current and newer therapies through a patient case.
Featured Activity
 |
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. MASH represents a metabolic-driven array of multi-organ pathology that intersects with obesity, prediabetes, type 2 diabetes, and cardiovascular ailments. Many agents are currently in development for treatment of MASH, including glucagon-like peptide-1 receptor agonists (GLP1-Ras). Although not FDA-approved specifically for MASLD, GLP1-RAs is utilized for obesity and type 2 diabetes treatment. It has demonstrated the ability to reverse steatohepatitis, lower cardiovascular risk, and is considered safe for use across various stages of MASLD, regardless of fibrosis presence. This review outlines the role of GLP1-RAs in treating MASLD/MASH.